At a glance

The basics

What estradiol is approved to treat

Estradiol is a form of estrogen. Menopause happens when the ovaries make much less of it, and many symptoms follow from that drop. FDA-approved estradiol products are labeled for the treatment of moderate to severe hot flashes and night sweats, which doctors call vasomotor symptoms. They are also labeled for moderate to severe vaginal and vulvar dryness, burning and pain with sex, and for prevention of bone loss after menopause.

Two of those labeled uses come with a limit. If vaginal symptoms are your only problem, the label tells doctors to consider a vaginal product first. If bone protection is your only goal, the label says to consider other options first. Estradiol is a good fit when you also have hot flashes, or when other bone medicines are not right for you.

Estradiol is not approved to treat weight gain, brain fog, low mood or low energy. Some women feel better in those areas once sleep and hot flashes settle. That is a side effect of treating the main symptoms, not a promise. Individual results vary.

Forms

Patch, gel, spray, pill or vaginal: how the route changes things

The same hormone behaves differently depending on how it enters your body. A pill is absorbed through the gut and passes through the liver first. Skin products and vaginal products skip that first pass. That difference is the main reason doctors pick one route over another.

What the clot data show

A French case-control study (ESTHER) found that women on oral estrogen had about four times the odds of a first blood clot in the leg or lung compared with non-users. Women on transdermal estrogen had odds close to one, meaning no clear increase. A large UK analysis in 2019 found the same pattern: oral therapy raised the odds of clots, and transdermal therapy did not clearly do so. Both are observational studies, so they show a link, not proof of cause. Still, they are why many doctors lean toward the skin for women with clot risk factors.

The evidence

What the Women’s Health Initiative showed, and what came after

The Women’s Health Initiative (WHI) is the large randomized trial that changed how doctors think about hormone therapy. In 2002 the estrogen-plus-progestin arm was stopped early. Compared with placebo, every 10,000 women taking it for a year had about 7 more heart events, 8 more strokes, 8 more lung clots and 8 more invasive breast cancers. They also had fewer hip fractures and fewer colon cancers.

The estrogen-alone arm, in women who had had a hysterectomy, told a different story. It raised stroke risk by about 12 events per 10,000 women per year and lowered hip fractures. It did not raise heart disease. After more than 20 years of follow-up, breast cancer was lower in the estrogen-alone group and higher in the estrogen-plus-synthetic-progestin group.

Two things limit how far these results stretch. The women averaged 63 years old, and most were well past menopause when they started. The trials also used one oral estrogen (conjugated equine estrogens) and one synthetic progestin (medroxyprogesterone). They did not test patches, gels or estradiol itself.

The timing question

When the WHI results were broken out by age, the extra risk per 10,000 women per year was about 12 for ages 50 to 59 and 38 for ages 70 to 79. A randomized trial called ELITE tested the timing idea directly with oral estradiol. In women within six years of menopause, artery thickening progressed more slowly on estradiol than on placebo. In women ten or more years past menopause, there was no such difference. That trial measured artery thickness, not heart attacks, so it supports the timing idea without settling it.

The Menopause Society’s 2022 position statement takes this view: for healthy women who are under 60 or within 10 years of menopause and have no contraindications, the balance of benefit and risk is generally favorable for treating bothersome symptoms. Starting later, or continuing for years, needs a closer look at your own risks. It is a judgment made with your doctor, not a default.

Safety

The boxed warnings, in plain words

For two decades, estrogen labels carried a boxed warning, the strongest kind the FDA uses. Here is what the older box said, in everyday language.

• Endometrial cancer. Estrogen taken alone raises the risk of cancer of the uterine lining in a woman who has a uterus. Adding a progestogen lowers that risk.
• Heart disease and stroke. Estrogen with or without a progestin raised the risk of stroke and blood clots, and estrogen plus a progestin raised heart attack risk, in the WHI.
• Probable dementia. In women 65 and older, the WHI saw more cases of probable dementia on hormones than on placebo.
• Breast cancer. Estrogen plus a progestin raised the risk of invasive breast cancer in the WHI.

Safety

Who should not use estradiol

The estradiol patch label lists the conditions below as reasons not to use it. Other estradiol products carry similar lists.

• Vaginal bleeding that has not been explained
• Breast cancer, or a history of it, and other cancers that depend on estrogen
• A current blood clot in the leg or lung, or a history of one
• A current or past heart attack or stroke
• Known liver disease
• A known clotting disorder such as protein C, protein S or antithrombin deficiency
• A past severe allergic reaction to estradiol or any ingredient in the product

Other things change the plan without ruling it out. Migraine with aura, high triglycerides, gallbladder disease, a strong family history of breast cancer and smoking all matter. So do some medicines. St. John’s wort, carbamazepine, phenobarbital and rifampin can lower estrogen levels. Some antifungals and antibiotics, such as ketoconazole and clarithromycin, can raise them.

The pairing

Why a woman with a uterus needs a progestogen

Estrogen tells the lining of the uterus to grow. Without a progestogen to balance it, the lining can overgrow, and that overgrowth can lead to cancer. The PEPI trial showed this directly. Over three years, 27.7 percent of women taking estrogen alone developed simple hyperplasia, compared with 0.8 percent on placebo. Women who took estrogen with a progestin or with micronized progesterone had rates close to placebo.

If you have had a hysterectomy, there is no lining to protect, and estrogen is usually taken alone. We cover the choices, including micronized progesterone and synthetic progestins, on our progesterone page.

Follow-up

Monitoring, and how long to stay on it

The goal is the lowest dose that controls your symptoms for as long as you need it. The patch label tells doctors to try lowering the dose or stopping every three to six months. We take that seriously. Here is what a follow-up looks like.

• A symptom review, so the dose is set by how you feel and not by a number on a lab report
• Blood pressure, and a fresh look at your clot, cancer and cardiovascular history
• A check that your breast cancer screening and cervical screening are current
• A thyroid recheck if you take levothyroxine, since oral estrogen can change the dose you need
• Prompt evaluation of any unexpected vaginal bleeding

Stop estradiol and call for care if you have sudden vision loss, a new severe headache, chest pain, a swollen painful leg, or shortness of breath. Some doctors also ask you to pause it before major surgery or a long period of bed rest.

A common question

Bioidentical estradiol: FDA-approved products versus compounded ones

Estradiol is bioidentical by definition. Its structure matches the estradiol your ovaries made. So the word does not tell you whether a product is a good one. Many FDA-approved products are bioidentical, including estradiol patches, gels, vaginal inserts and a capsule that combines estradiol with micronized progesterone. These products are tested for dose, purity and absorption, and the FDA reviews them.

When a pharmacy blends estradiol into a cream, troche or pellet to order, the product is compounded. Compounded drugs are not FDA-approved. They are not evaluated by the FDA for safety, effectiveness or quality. The American College of Obstetricians and Gynecologists says compounded bioidentical therapy should not be prescribed routinely when FDA-approved options exist, and notes that “bioidentical” is used by some pharmacies as a marketing term. The Endocrine Society’s 2016 statement reaches a similar conclusion. Both groups call for better trials before anyone can say custom compounding does more than approved products.

Summit’s role

How Summit uses estradiol

Summit Metabolic Health is a telehealth-only practice, so everything starts with a physician review of your history, symptoms and labs. Dr. Miranda prescribes estrogen and progesterone for perimenopausal and menopausal women when the evaluation supports it. We prefer FDA-approved products where one fits. If a compounded product is the better fit for you, it comes from an independent state-licensed pharmacy, and we tell you plainly that it is not FDA-approved or evaluated by the FDA.

Hormones are one piece. Sleep, weight, blood sugar and strength all shift around menopause, and we look at them together. You can read how we think about it in our hormone replacement therapy guide and our bioidentical hormone guide for women. Membership details and fees are on the pricing page. Hormone therapy is a prescription medicine. A physician decides whether it is right for you, and not everyone who applies will be a candidate.

Keep reading

Related medications

Sources

Where this comes from

All retrieved November 10, 2026.

1. Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women (WHI). JAMA 2002 https://pubmed.ncbi.nlm.nih.gov/12117397/
2. Anderson GL et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy (WHI). JAMA 2004 https://pubmed.ncbi.nlm.nih.gov/15082697/
3. Manson JE et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the WHI trials. JAMA 2013 https://pubmed.ncbi.nlm.nih.gov/24084921/
4. Chlebowski RT et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the WHI trials. JAMA 2020 https://pubmed.ncbi.nlm.nih.gov/32721007/
5. Hodis HN et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med 2016 https://pubmed.ncbi.nlm.nih.gov/27028912/
6. Canonico M et al. Hormone therapy and venous thromboembolism: impact of the route of estrogen administration (ESTHER). Circulation 2007 https://pubmed.ncbi.nlm.nih.gov/17309934/
7. Vinogradova Y et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ 2019 https://pubmed.ncbi.nlm.nih.gov/30626577/
8. The PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996 https://pubmed.ncbi.nlm.nih.gov/8569016/
9. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022 https://pubmed.ncbi.nlm.nih.gov/35797481/
10. ACOG Clinical Consensus No. 6. Compounded bioidentical menopausal hormone therapy. Obstet Gynecol 2023 https://pubmed.ncbi.nlm.nih.gov/37856860/
11. Endocrine Society Scientific Statement. Compounded bioidentical hormones in endocrinology practice. J Clin Endocrinol Metab 2016 https://pubmed.ncbi.nlm.nih.gov/27032319/
12. Climara (estradiol transdermal system) prescribing information, DailyMed https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864